-
SinoMab BioScience’s Suciraslimab Files for Market Approval in China for Rheumatoid Arthritis
•
Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that a market approval filing has been submitted for its suciraslimab (SM03) to the National Medical Products Administration (NMPA) in China. The CD22 monoclonal antibody (mAb) is seeking its first indication approval as a treatment for rheumatoid arthritis (RA).…
-
Weight-Loss Drug Demand Pushes Novo Nordisk to Peak European Market Capitalization
•
Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) achieved a significant milestone last week when it transiently reached the top position among European companies by market capitalization, reaching USD 421 billion including unlisted stocks. This temporary ascension to the peak of European market capitalization was driven by the demand for the…
-
Janssen Sues Distributors Over Counterfeit Antiretroviral Therapies in the US
•
Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, filed a lawsuit last week against pharmaceutical distributors selling counterfeit versions of its antiretroviral therapies to three pharmacies in the United States. The move comes after the company became aware of the situation in 2020. The products primarily affected include the complete…
-
Columbia University Study Weighs Cost-Effectiveness of Weight-Loss Treatments for Adolescents
•
Researchers at US Columbia University have published the results of a study estimating the cost-effectiveness of Novo Nordisk’s (NYSE: NVO) injections Wegovy (semaglutide) and Saxenda (liraglutide), as well as Vivus’s (NASDAQ: VVUS) pill Qsymia (phentermine + topiramate) for weight-loss interventions in adolescents. The study utilized a simulated cohort of 100,000…
-
Shanghai Pharmaceuticals Executives Under Investigation for Serious Disciplinary Violations
•
China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has disclosed that several former executives are suspected of serious violations of discipline and law. Pan Deqing, the company’s former vice-president, Chen Binhua, former general manager of subsidiary SPH NO.1 Biochemical & Pharmaceutical Co., Ltd, and Li Ping, former…
-
BDgene Technology Announces Clinical Milestone for CRISPR-Cas9 Gene Therapy in HSK
•
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced the conclusion of three clinical research treatments using its HELP technology, based on the CRISPR-Cas9 gene editing tool, for herpes simplex keratitis (HSK). Preliminary positive results have been published in the journal Molecular Therapy, in an article titled “In Vivo…
-
Sanofi Announces Management Restructuring with New Leadership Roles in China
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced a significant restructuring of its management structure in China, introducing three new global management positions and two new leadership teams to enhance operations and strategic alignment within the region. New Global Management Posts in ChinaThe newly created positions include the role of…
-
ImmuneOnco Biopharmaceuticals Begins Trading on HKEX with Successful IPO
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) marked its debut on the Hong Kong Stock Exchange this morning, with a positive start as its share price surpassed the issuance price of RMB 18.6 per share in early trading. The initial public offering (IPO) is anticipated to raise over HKD 300…
